Creatv Bio Studies Highlight Importance of Blood Monitoring in Cancer Treatment
Creatv Bio presented five posters at the 2026 AACR Annual Meeting, demonstrating the significance of monitoring PD-L1, mitotic CTCs, and CAMLs in blood for predicting treatment responses and disease prognosis in various types of metastatic cancer. Key findings revealed correlations between aggressive disease and circulating tumor cells, the potential of PD-L1 monitoring in enhancing treatment strategies, and the role of combined biomarker evaluation in risk stratification. The studies utilized Creatv’s LifeTracDx® blood test to analyze these biomarkers.
MONMOUTH JUNCTION, N.J., May 20, 2026 /PRNewswire/ — Creatv Bio, a Division of Creatv MicroTech, Inc. (“Creatv”), a cancer diagnostic blood testing company, presented five posters in conjunction with several research collaborators at the 2026 AACR Annual Meeting, held in San Diego, CA.
1. Mitosis in circulating tumor cells correlates with highly aggressive disease in metastatic breast cancer
Abstract: 1065
Key Finding: Circulating tumor cells (CTCs) undergoing mitosis is indicative of highly aggressive disease with poor survival rates.
2. Monitoring PD-L1 in tumor macrophage fusion cells in blood correlates to PD-L1 checkpoint inhibitor responses in metastatic breast cancer
Abstract: 1025
Key Finding: Monitoring PD-L1 in tumor macrophage fusion cells (TMFCs) serves as a real-time blood biomarker that predicts Immune Checkpoint Inhibitor (ICI) responses in metastatic breast cancer.
3. Combining circulating tumor cells and cancer associated macrophage-like cells enhances risk stratification models in pan-cancer metastatic disease
Abstract: 1068
Key Finding: Cancer associated macrophage-like cells (CAMLs) are a subtype of TMFCs. Simultaneous quantification of both CTCs and CAMLs allows for more accurate patient risk stratification.
4. Leronlimab induces PD-L1 expression and is associated with long term survival with an ICI in PD-L1 low metastatic TNBC
Abstract: 1033
Key Finding: Monitoring PD-L1 expression on CTCs and CAMLs identifies PD-L1 upregulation after treatment with leronlimab.
5. Preliminary results of a phase 2 study of leronlimab in combination with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer
Abstract: 6466
Key Finding: Monitoring CTCs, CAMLs and ctDNA show promise as early assessments for clinical response when treated with leronlimab.
Creatv’s LifeTracDx® blood test utilized CellSieve microfilters to isolate, collect and measure both CTCs and CAMLs (number and size) in each of the clinical studies above.
About Creatv Bio
Creatv Bio operates a CLIA-certified cancer diagnostics laboratory, supporting its pharmaceutical partners with research and investigational studies.
Creatv’s LifeTracDx® blood test is an analytically validated assay used for research and development. Current applications include evaluation of circulating biomarkers supporting translational and exploratory studies.
The assay is intended for research and investigational use only and is not for use in clinical diagnosis, prognosis, treatment selection, or disease monitoring.
Creatv contacts (creatvbio.com):
|
Daniel L Adams |
Ron Baker |
|
Chief Scientific Officer |
Chief Business Officer |
|
732-783-7132 (office) |
301-785-5185 (mobile) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/creatv-bio-studies-presented-at-aacr-annual-meeting-showing-importance-of-monitoring-pd-l1-mitotic-ctcs-and-camls-in-blood-302777505.html
SOURCE Creatv MicroTech, Inc.